Reference: Project Cardio
Asking Price: Offers Invited
C£700,000 Investment to date on:
• R & D
• Design, IPR, CE Certification, EU Design Registration, Trademarks, Patents, Approvals
• Full proof of concept and manufacture (UK)
• Existing customer base
• FDA Registration and licensed US Agent recently appointed
This rare and unique opportunity exists to acquire, by way of a share purchase, all of the issued share capital in this UK Limited company (“the Business”) that has developed a new, innovative and unique disposable medical device for use in cardiovascular intervention.
The use only once device is used following a coronary angiogram which may proceed to intervention.
Launched some 4 years ago, the Business has worked tirelessly since inception with the medical sector here within the UK to design, develop and bring to market a new highly innovative product that makes patent hemostasis easier to preserve the radial artery. The procedures this device enhances are carried out throughout the world on a day to day basis and the rate of these procedures is growing year on year. Typical procedures include an angiogram which always precedes an angioplasty also known as a PCI (Percutaneous Coronary Intervention) when the radial artery in the wrist is used to access the arterial vascular system to reach the heart.
Further market specifics can be provided upon completion of our NDA.
The owners have invested significant resource in developing this new product that has distinct advantages over the current market leader especially with the global shift from femoral artery to radial artery access. The opportunity now exists to actively promote and introduce this product to the medical world and roll it out on a National/European and Global scale. Investment to date has included the provision and registration of all the necessary Trademarks, IPR and most recently CE Certification.
The business has collaborated with leading medical specialists, designers, consultants, manufacturers and advisers to ensure the device is what the clinicians require and believe it will certainly enhance current procedure outcomes.
The business has also attained ISO13485 certification ensuring it has a robust quality management system in place to ensure it continues to meet all the necessary regulations now and in the future.
Product Costings/Market :
The company has a proven device concept and has carried out some small batch manufacturing within the UK with trusted supply partners. Current costing allows for a very healthy gross profit margin when selling to a distributor whilst still enabling the distributor to make a significant margin themselves- see chart below for illustration of revenue generation for angiogram procedures alone by achieving 5% and 15% market share over the next 4 years. However the business could certainly benefit from additional support in this area in terms of commercial rollout and future scalability which could considerably enhance these figures.
Angiograms w/wide yr 2022 12,000,000
50% Radial Procedures 6,000,000 5% mkt share= 300,000 units= £600,000 GP p.a.
60% Radial Procedures 7,200,000 5% mkt share= 360,000 units= £720,000 GP p.a.
Angiograms w/wide yr 2025 14,000,000
60% Radial Procedures 8,400,000 15% mkt share= 1,260,000 units= £2,898,000 GP p.a.
70% Radial Procedures 9,800,000 15% mkt share= 1,470,000 units= £3,381,000 GP p.a.
**Above numbers are based on current UK manufacturing costs
Figures based on company selling to distributors with a 57% mark up in 2022, 70% mark up in 2025 due to reduced supply price based on volumes.
Figures based on distributor selling to end- users with a 64% mark up. Product is still very price competitive to end user.
Radial access is steadily increasing worldwide.
The Company has spent significant time, resource and effort in developing this “idea” from the drawing board to CE certified device. It now requires a new owner with the necessary commercial acumen to take it to the larger market place and fully monetise the huge opportunities that exist.
At time of going to market the company has achieved some new low level sales within the UK but more importantly has trials ongoing in several key cardio centres within the UK and samples being reviewed in USA that should stimulate significant interest moving forwards.
Note: The Company is now a registered operator with the FDA in USA and has recently appointed a US Agent which means they are now licensed to sell the device in USA.